37results about "C-reactive protein" patented technology

Compositions and methods are provided for the treatment of fibrosis related disorders utilizing the ratio of the concentration of serum amyloid P(SAP) to C-reactive protein (CRP) in a patient. The methods may further comprise determining the R131 / H131 polymorphism of FcγRIIA. Diagnostic methods are also provided.

An object of the present invention is to provide a method and a reagent for measuring the subject substances containing high concentration of C-reactive protein without dilution while avoiding prozone phenomenon. C-reactive protein is measured with a compound having a phosphrylcholine group and a cationic group shown by the general formula (I) [in the formula (I), where R1, R2 and R3 stand for a hydrogen atom, substituted or non-substituted alkyl, or substituted or non-substituted alkenyl, and X- stands for an inorganic anion or an organic anion) and an antibody to C-reactive protein. Or, C-reactive protein is measured with a surface active agent having a phosphorylcholine group, a surface active agent having a cationic group shown by the formula (II) [Y1 stands for a hydrophobic group, and R1, R2 and R3 stand for a hydrogen atom, substituted or non-substituted alkyl, or substituted or non-substituted alkenyl], and an antibody to C-reactive protein. As an antibody to C-reactive protein, an antibody carried by a water-insoluble carrier such as latex made from polystyrene is preferable.

The use of inhibitors of long pentraxin PTX3 for the preparation of a medicament for the prevention and treatment of autoimmune diseases and of degenerative diseases of bone and cartilage is described.

An aptamer specifically binding to C-reactive protein (CRP) is provided. The aptamer includes a following nucleotide sequence: 5′-angngggngnntgnnt-3′, wherein n is a nucleotide selected from a, t, c and g.

The instant invention relates to a transgenic, non-human animal that carries a mutation in the gene encoding C-reactive protein (CRP). Preferably, the invention relates to an animal comprising a homozygous CRP-deficient mouse and techniques for producing such animals. The invention also relates to organs, tissues, cells, cell lines and sub-cellular fractions derived from such animals. Techniques for generating total or tissue-specific CRP knockout animals are also described. The invention further relates to the use of such knockout animals for the study of the role of CRP proteins in vivo or ex vivo, particularly in relation to its role in inflammatory pathway and in the etiology human diseases.

The invention belongs to the biotechnological field, and provides a polypeptide. The polypeptide includes two dominant antigen epitopes of the recombinant canine C-reactive protein (CRP). The polypeptide is coupled with the KLH protein for enhancing the immune effect. The invention provides a canine CRP recombinant protein. The canine CRP recombinant protein mainly includes the two dominant antigen epitopes. Specific to the aim of increasing the yield of the recombinant protein in a prokaryotic expression system, the recombinant protein amino acid sequence is converted into a corresponding nucleotide sequence by using an escherichia coli preferred codons, the nucleotide sequence is subjected to chemical synthesis, and the recombinant protein expression vector is built. The invention further relates to the preparation of the recombinant protein mono-clone antibody, the mono-clone antibody is prepared by antigen immunization, cell fusion and a plurality of screening, the mono-clone antibody is purified, the fluorescent microsphere is marked respectively, the best mono-clone pair determined through orthogonal experiment, the recombinant canine C-reactive protein can be applied to diagnosis of inflammation.

The use of inhibitors of long pentraxin PTX3 for the preparation of a medicament for the prevention and treatment of autoimmune diseases and of degenerative diseases of bone and cartilage is described.

The invention relates to a specific protein marker for ovarian cancer diagnosis and a preparation method of the protein marker. The specific protein marker comprises the components including C reactive protein in serum exosome, solute transport protein family 11 member 2, ubiquitin-like PHD and ring finger domain protein 1. The preparation method comprises the following steps of protein extraction, pancreatin enzymolysis, TMT labeling, HPLC grading, liquid chromatography-mass spectrometry analysis, database search, protein identification, protein differential expression analysis, protein annotation and bioprotein marker screening. The protein marker has the advantages that (1) the marker has relatively high sensitivity and specificity; (2) ovarian malignant tumors can be distinguished frombenign tumors / healthy people; and (3) the preparation process is clear, the operability is high, and the repeatability is high.

The invention belongs to the technical field of protein purification, and discloses a phospholipid organic polymer whole material and a preparation method and application thereof. The method comprisesthe steps that phospholipid monomeric compound, crosslinking agent, porogen and initiator are mixed and then poured into a container after ultrasonic dissolving and deaeration are conducted, aggregation reaction is conducted under the temperature of 40-70 DEG C or under ultraviolet irradiation, and the phospholipid organic polymer whole material is obtained. The phospholipid organic polymer wholematerial has the advantages of high reproducibility, good biocompatibility and protein nonspecific adsorption resistance, and the existing defects of a traditional CRP purified material are effectively overcome. According to the material, by taking the phospholipid organic polymer whole material as an absorbent purifying standard protein mixed sample or an actual sample, CRP proteins with high purity can be obtained simply by one purifying strategy, the operation is easy, and the recovery rate is close to 100%.

The present invention provides methods and systems to accurately detect and measure in a biological sample from a patient, endogenous antibodies, e.g., IgA, to inflammatory proteins, which antibodies are useful as diagnostic markers for inflammatory conditions, including bowel disease (IBD), in patients. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.

Disclosed are a highly efficient method for production of heterologous proteins performed by utilizing microorganisms, as well as fusion proteins, and an antiserum. The method includes a method for production of a protein (A) in the form of a fusion protein, comprising the steps of (a) preparing a DNA which codes for a fusion protein comprising the peptide chain forming the protein (A) and the C-terminal peptide or its fragment (B) of the Cry proteins produced by Bacillus thuringiensis, and (b) introducing the DNA into a host bacterium to transform the same, and (c) allowing the fusion protein to be expressed in the transformed host bacterium, as well as a method for production of the protein (A) itself comprising a further step of removing the peptide chain (B) from the fusion protein obtained.

An aptamer specifically binding to C-reactive protein (CRP) is provided. The aptamer includes a following nucleotide sequence: 5′-angngggngnntgnnt-3′, wherein n is a nucleotide selected from a, t, c and g.

The present invention provides a biomarker for detecting and diagnosing polypoidal choroidal vasculopathy (PCV) of human eyes, including levels of hyperhomocysteinemia that are identified, wherein elevated levels of hyperhomocysteinemia are highly associated with PCV of the human eyes. In addition, the present invention further provides a method for detecting and diagnosing PCV of the human eyes.

An object of the present invention is to provide a polydimethylsiloxane substrate to which a peptide having an affinity for polydimethylsiloxane (PDMS) is bound; a method for immobilizing a target protein on a polydimethylsiloxane substrate; a peptide having an affinity for PDMS; a polynucleotide encoding a peptide having an affinity for PDMS; and a vector using thereof. A polydimethylsiloxane substrate to which a peptide having an affinity for polydimethylsiloxane is bound, the peptide comprising the following peptide (1a) or (1b), or a fragment thereof: (1a) a peptide comprising an amino acid sequence represented by at least one member selected from the group consisting of SEQ ID NOs: 1 to 9; and (1b) a peptide comprising the amino acid sequence of (1a) in which one or more amino acids are deleted, substituted, and / or added, the peptide having an affinity for polydimethylsiloxane.

The invention discloses a preparation method of recombinant human C-reactive protein. The method comprises the following steps: acquiring a protein sequence of the human C-reactive protein from NCBI;artificially optimizing and synthesizing a C-reactive protein encoding gene according to codon bias characteristics of escherichia coli; further constructing an expression vector of the human C-reactive protein; converting the expression vector into the escherichia coli for induced expression; and purifying an expression product to obtain pure recombinant protein. ELISA detection results show thatthe immunological characteristics of the expressed and purified recombinant human C-reactive protein are very similar to those of natural human C-reactive protein, and the detection requirements canbe met. In addition, the purification process of the recombinant human C-reactive protein is beneficial to quality control and the requirement of industrial production are met.

The present invention improves the accuracy of a latex reagent-based immunoassay in a CRP high concentration range.　Provided is a C-reactive protein produced by genetic recombination, wherein 55% or more of the N-termini of the C-reactive protein are pyro-glutamylated.

The present invention provides a biomarker for detecting and diagnosing polypoidal choroidal vasculopathy (PCV) of human eyes, including levels of hyperhomocysteinemia that are identified, wherein elevated levels of hyperhomocysteinemia are highly associated with PCV of the human eyes. In addition, the present invention further provides a method for detecting and diagnosing PCV of the human eyes.

The application provides methods for determining a patient's risk for developing fibrosis or a fibrosis-related disorder. Concentrations of C reactive protein (CRP) and serum amyloid protein (SAP) are measured from a biological sample to determine the SAP-to-CRP ratio. This ratio can then be compared with one or more SAP-to-CRP reference ratios to determine a patient's risk for developing a fibrosis related disorder. The diagnostic methods can also be used to determine the severity of fibrosis in a patient afflicted with such a disease. Furthermore, methods for treating patients having a fibrosis-related disorder are provided. For example, a patient that has a lower SAP-to-CRP ratio than one or more reference values may be treated with an SAP agonist and / or CRP antagonist to treat or prevent a fibrosis disorder. The methods may further comprise determining the R131 / H131 polymorphism of FcγRIIA as a risk factor for developing fibrosis or a fibrosis-related disorder.

The present invention relates to a method for diagnosing the degree of arteriosclerotic stenosis in a subject including determining the amount of CRP or LPa in a sample of the subject and comparing the determined amount to a reference whereby the degree of arteriosclerotic stenosis is determined. The present invention also contemplates a method for identifying a subject in need of prevention or therapy of arteriosclerosis. Further, devices and kits are encompassed for carrying out the methods.

The invention discloses a polyantigen and a preparation method thereof. Wherein the polyantigen is formed by self-assembly of fusion protein, and the fusion protein comprises capsid protein and C-reactive protein. The multi-antigen is of a virus-like particle structure, wherein the C-reactive protein is located on the outer side of the virus-like particle structure. The polymer antigen is an icosahedron polymer particle, partially simulates spatial sites of a natural antigen pentamer, and improves the recognition efficiency of the generated antibody on the natural antigen.

The invention belongs to the biotechnological field, and provides a polypeptide. The polypeptide includes two dominant antigen epitopes of the recombinant canine C-reactive protein (CRP). The polypeptide is coupled with the KLH protein for enhancing the immune effect. The invention provides a canine CRP recombinant protein. The canine CRP recombinant protein mainly includes the two dominant antigen epitopes. Specific to the aim of increasing the yield of the recombinant protein in a prokaryotic expression system, the recombinant protein amino acid sequence is converted into a corresponding nucleotide sequence by using an escherichia coli preferred codons, the nucleotide sequence is subjected to chemical synthesis, and the recombinant protein expression vector is built. The invention further relates to the preparation of the recombinant protein mono-clone antibody, the mono-clone antibody is prepared by antigen immunization, cell fusion and a plurality of screening, the mono-clone antibody is purified, the fluorescent microsphere is marked respectively, the best mono-clone pair determined through orthogonal experiment, the recombinant canine C-reactive protein can be applied to diagnosis of inflammation.

The present invention discloses a method for preparing heterodimer protein. The specific steps are as follows: firstly activating proteins: taking SPDP (3-(2-pyridinedimercapto) propionate N-hydroxysuccinimide ester) to be mixed with a protein 1 in a buffer and taking HS-PEG-NHS (sulfhydryl PEG-N-hydroxysuccinimide) to be mixed with a protein 2 in a buffer to separately obtain an activated protein1 and an activated protein 2; and mixing the activated protein 1 and the activated protein 2, purifying the obtained product and conducting preservation at low temperature. The protein product prepared by the method is an oligomer with low molecular weight, the product is mostly heterodimers, all used reagents can stably exist in a water phase, and the method has good repeatability, stability andreliability.

The present invention discloses a coding gene sequence and application of porcine C-reactive protein and monoclonal antibody. By optimizing the sequence, the porcine C-reactive protein gene is artificially synthesized, and the synthesized gene is inserted into the pET-28a vector, and then co-transformed into the BL21(DE3) host bacterium together with the chaperone plasmid pTF16 to co-express porcine C-reactive protein and the chaperone protein tig to promote the soluble expression of porcine C-reactive protein; a hybridoma cell is obtained by immunizing with this recombinant protein, and the secreted monoclonal antibody contains the heavy chain variable region named VH and the light chain variable region VL, and is composed of the complementarity-determining regions CDR1, CDR2, CDR3 and the framework region. Experiments prove that the recombinant expressed porcine C-reactive protein has high specificity, and the monoclonal antibody produced by preparation and screening through the recombinant protein can be used in a protein detection kit. The porcine C-reactive protein ELISA detection kit of the present invention is used to detect porcine C-reactive protein, can effectively detect the concentration of porcine C-reactive protein in the serum of pig herds, detect the group inflammation level, and evaluate the health level of pig herds in pig farms.

Disclosed are a highly efficient method for production of heterologous proteins performed by utilizing microorganisms, as well as fusion proteins, and an antiserum. The method includes a method for production of a protein (A) in the form of a fusion protein, comprising the steps of (a) preparing a DNA which codes for a fusion protein comprising the peptide chain forming the protein (A) and the C-terminal peptide or its fragment (B) of the Cry proteins produced by Bacillus thuringiensis, and (b) introducing the DNA into a host bacterium to transform the same, and (c) allowing the fusion protein to be expressed in the transformed host bacterium, as well as a method for production of the protein (A) itself comprising a further step of removing the peptide chain (B) from the fusion protein obtained.

In immunoassay using a latex reagent, the correctness of immunoassay in a CRP high-concentration range is improved. The recombinant C-reactive protein is a C-reactive protein produced by gene recombination, and 55% or more of the N-terminus of the C-reactive protein is pyroglutaminated.

The purpose of the present invention is to provide: a polydimethylsiloxane substrate obtained through the bonding of peptides having an affinity for polydimethylsiloxane (PDMS); a method for immobilizing a target protein on the polydimethylsiloxane substrate; peptides having an affinity for PDMS; polynucleotides for coding the peptides having an affinity for PDMS; and vectors and the like that use the polynucleotides. A polydimethylsiloxane substrate obtained through the bonding of peptides having an affinity for polydimethylsiloxane, said peptides comprising (1a) or (1b) below or fragments thereof. (1a) A peptide comprising an amino acid sequence represented by at least one sequence selected from the group consisting of SEQ ID Nos. 1 to 9. (1b) A peptide having an affinity for polydimethylsiloxane, and comprising an amino acid sequence in which one or a plurality of amino acids have been deleted, substituted and / or added in the amino acid sequence of (1a).

The invention provides a method for improving the protein expression quantity of a protein expression system. The method comprises the following steps: replacing a first codon behind an initiation codon in a gene of a target protein with a codon of which the third site is G of the same amino acid; compared with other methods, the method can greatly improve the protein recombinant expression yield and reduce the protein production cost, and is high in cost performance.

The invention discloses a composite quality control product based on multiple diagnostic marker-specific epitope polypeptide molecules linked by ferritin nanoparticle carriers and a preparation method thereof. Through antibody detection and epitope analysis techniques, most of the The dominant epitope of the diagnostic marker protein is located, and then linked to the ferritin molecule by connecting esters to form a "Fer-Linker-Epitope Peptide" complex, and the synthetic gene sequence of the complex is transferred into the prokaryotic large intestine through a specific vector Bacillus recombinant expression, so that the composite antigen (quality control product) containing the dominant epitope polypeptide molecules of multiple diagnostic markers can be detected by multiple diagnostic reagents at the same time. The quality control product of the invention has high detection efficiency, low cost and excellent stability, and can be stored stably for a long time under the condition of 2-8°C.

The invention belongs to the technical field of protein purification, and discloses a phospholipid organic polymer whole material and a preparation method and application thereof. The method comprisesthe steps that phospholipid monomeric compound, crosslinking agent, porogen and initiator are mixed and then poured into a container after ultrasonic dissolving and deaeration are conducted, aggregation reaction is conducted under the temperature of 40-70 DEG C or under ultraviolet irradiation, and the phospholipid organic polymer whole material is obtained. The phospholipid organic polymer wholematerial has the advantages of high reproducibility, good biocompatibility and protein nonspecific adsorption resistance, and the existing defects of a traditional CRP purified material are effectively overcome. According to the material, by taking the phospholipid organic polymer whole material as an absorbent purifying standard protein mixed sample or an actual sample, CRP proteins with high purity can be obtained simply by one purifying strategy, the operation is easy, and the recovery rate is close to 100%.